Edoxaban

Cada, Dennis J.; Baker, Danial E.; Ingram, Kyle

doi:10.1310/hpj5007-619

Cited by 4 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This gives rise to the major metabolite of edoxaban M-4, which is active but accounts for less than 10% of the total edoxaban plasma exposure [118]. Minimal metabolism also takes place via the phase I processes of oxidation and conjugation, mediated by the CYP3A4 enzymes [119]. Edoxaban also undergoes phase 2 metabolism through glucuronidation.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation

Fawzy

Lip

2019

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction:The availability of non-vitamin K antagonist oral anti-coagulants alongside vitamin K antagonists has offered a variety of options for anti-coagulation, but has also necessitated a good understanding of the pharmacological properties of each of these drugs prior to their use, to maximise the therapeutic benefit and minimise patient harm Areas covered: This review article outlines the pharmacokinetic and pharmacodynamic profiles of the currently licensed NOACs and VKAs that are most commonly used in clinical practice, with the aim of demonstrating how variations in these processes contribute to their use in clinical practice. A literature search was conducted on PubMed using keywords and relevant articles published by the 31 st of December 2018 were included. Expert opinion:The effect of a drug is determined by a combination of elements which include patient characteristics and external influences, in addition to its pharmacokinetic and pharmacodynamic properties. A good understanding of this is essential. Despite the wealth of information available, particularly on VKAs, our knowledge on the pharmacology responsible for certain drug effects and inter-individual variations is still limited. Increasing efforts are being made to uncover these and includes focus on pharmacogenomics and drug transporter proteins.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation

Fawzy

Lip

2019

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation

Bortman

Mitchell

Naveiro

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Direct oral anticoagulants have been an increasingly used class of drugs in the setting of nonvalvular atrial fibrillation, defying vitamin K antagonists’ monopoly when it comes to anticoagulation due to its several limitations. Direct oral anticoagulants (DOACs) have entered the market as a noninferior and safer option in comparison with vitamin K antagonists, as their respective phase III clinical trials proved. The aim of this article was to update and summarize data on their clinical pharmacology and to review real‐world data to know their comparative effectiveness and safety. We performed a systematic review using PubMed, Google Scholar, Embase, and Web of Science as search engines. Regarding pharmacodynamics, there were no substantial changes reported from their original profile. There were many advances in the knowledge about clinical pharmacokinetics of DOACs that have had a direct impact on their clinical use, mainly related to drug‐drug interactions. In a real‐world setting, DOACs have shown to be noninferior in preventing thromboembolic events compared to vitamin K antagonists. In regards to safety, DOACs have shown a lower bleeding risk relative to warfarin. Comparison between DOACs has demonstrated rivaroxaban to have the highest bleeding risk. Overall, the evidence gathered showed few changes from the original data presented in phase III clinical trials, concluding that their real‐world use coincides greatly with them.

show abstract

HNO – allgemeine Aspekte

Koch

2016

HNO Fragen Und Antworten

View full text Add to dashboard Cite

Edoxaban

Cited by 4 publications

References 43 publications

Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation

Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation

Direct Oral Anticoagulants: An Updated Systematic Review of Their Clinical Pharmacology and Clinical Effectiveness and Safety in Patients With Nonvalvular Atrial Fibrillation

HNO – allgemeine Aspekte

Contact Info

Product

Resources

About